Page last updated: 2024-12-06

hexestrol bis(diethylaminoethyl ether)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hexestrol bis(diethylaminoethyl ether): minor descriptor (75-84); on-line & Index Medicus search HEXESTROL/AA (75-84); RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66143
CHEMBL ID1615358
CHEBI ID135759
SCHEMBL ID317407
MeSH IDM0262691

Synonyms (32)

Synonym
BB 0259580
hexestrol bis(diethylaminoethyl ether)
CHEBI:135759
AKOS000280972
diethylaminoethoxyhexestrol
2691-45-4
2,2'-((1,2-diethylethylene)bis(p-phenyleneoxy))bis(triethyl)amine
ubr09a3iff ,
einecs 220-261-6
unii-ubr09a3iff
hexestrol-4,4'-bis(2-diethylaminoethylether)
n,n,n',n'-tetraethyl-n,n'-(2,2'-(4,4'-(1,2-diethylethylen)diphenoxy)diethyl)diamin
CHEMBL1615358
FT-0683014
2,2'-[3,4-hexanediylbis(4,1-phenyleneoxy)]-bis(n,n-diethylethanamine)
AKOS016344219
SCHEMBL317407
ethanamine, 2,2'-((1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy))bis(n,n-diethyl-
4,4'-bis(.beta.-diethylaminoethoxy)-.alpha.,.beta.-diethyldiphenylethane
triethylamine, 2,2'''-((1,2-diethylethylene)bis(p-phenyleneoxy))bis-
hexestrol bis(.beta.-diethylaminoethyl) ether
2,2'-(3,4-hexanediylbis(4,1-phenyleneoxy))-bis(n,n-diethylethanamine)
4,4'-bis(2-diethylaminoethoxy)-.alpha.,.alpha.'-diethylbibenzyl
hexestrol bis(.beta.-diethylaminoethyl ether) [mi]
4,4'-bis(.beta.-diethylaminoethoxy)hexestrol
4,4'-diethylaminoethoxyhexestrol
3,4-bis(p-(.beta.-diethylaminoethoxy)phenyl)hexane
2,2'-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis(triethyl)amine
Q27291006
2-[4-[4-[4-[2-(diethylamino)ethoxy]phenyl]hexan-3-yl]phenoxy]-n,n-diethylethanamine
DTXSID40871539
n,n'-{hexane-3,4-diylbis[(4,1-phenylene)oxyethane-2,1-diyl]}bis(n-ethylethan-1-amine)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID540238Phospholipidosis-positive literature compound observed in mouse
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID540239Phospholipidosis-positive literature compound observed in dog
AID540241Phospholipidosis-positive literature compound observed in hamster
AID540237Phospholipidosis-positive literature compound observed in rat
AID540240Phospholipidosis-positive literature compound observed in rabbit
AID540236Phospholipidosis-positive literature compound observed in human
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (66.67)18.7374
1990's3 (16.67)18.2507
2000's2 (11.11)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.15 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]